Quell Therapeutics Revenue and Competitors

London, UK

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Quell Therapeutics's estimated annual revenue is currently $32.7M per year.(i)
  • Quell Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Quell Therapeutics has 211 Employees.(i)
  • Quell Therapeutics grew their employee count by 5% last year.

Quell Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Manufacturing OfficerReveal Email/Phone
3
Co-founder & VP BiologyReveal Email/Phone
4
Executive Assistant to Chief Medical Officer & Chief Business OfficerReveal Email/Phone
5
Executive Assistant to CMOReveal Email/Phone
6
VP QualityReveal Email/Phone
7
VP clinical operationsReveal Email/Phone
8
VP Supply Chain & External ManufacturingReveal Email/Phone
9
Director / Non-Clinical Group LeaderReveal Email/Phone
10
Director/Team Lead Discovery and New TechnologiesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M35-12%N/AN/A
#2
$16.3M1054%N/AN/A
#3
$107.2M49425%$292MN/A
#4
$2.6M83030%$631.7MN/A
#5
$18.1M117-8%$81MN/A
#6
$1.2M27112%$440MN/A
#7
$54.6M2820%$132.9MN/A
#8
$9.3M60-37%N/AN/A
#9
$21.2M13712%N/AN/A
#10
$408.2M164611%£994.6MN/A
Add Company

What Is Quell Therapeutics?

An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions. Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively across the business, taking ownership and accountability for the outcomes and results we delivery. Most of all we work with integrity to innovate and bring the best version of ourselves to the job every day.

keywords:N/A

N/A

Total Funding

211

Number of Employees

$32.7M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Quell Therapeutics News

2022-04-20 - Other news to note for April 28, 2022

Quell Therapeutics Ltd., of London, entered a collaboration for the co-development of an induced pluripotent stem cell (iPSC)-derived Treg...

2022-04-20 - Strategic Collaboration Set to Develop iPSC-derived Cell ...

Quell Therapeutics and Cellistic aim to develop next-gen platform for creation of off-the-shelf Treg cell therapies targeting a wide range...

2022-04-17 - Quell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-derived allogeneic T-regulatory (Treg) cell therapy platform

Quell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-derived allogeneic T-regulatory (Treg) cell therapy...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$29.5M2110%$2B
#2
$47.6M2116%N/A
#3
$56.4M211-10%N/A
#4
$52.7M2111%N/A
#5
$30.2M211N/AN/A